O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial
Bradley J. Monk(Creighton University), Takafumi Toita(Okinawa Prefectural Chubu Hospital), Xiaohua Wu(Fudan University Shanghai Cancer Center), Juan Carlos Vázquez Limón(Instituto Jalisciense de Cancerología), Qi Zhou(Chongqing University), R. Tarnawski(The Maria Sklodowska-Curie National Research Institute of Oncology), Masaki Mandai(Kyoto University), Ronnie Shapira‐Frommer(Sheba Medical Center), Umesh Mahantshetty(Homi Bhabha National Institute), Maria Del Pilar Estevez-Diz(Universidade de São Paulo), Francisco Ramirez Godinez(Hospital Civil de Guadalajara), Szilvia Varga(National Institute of Oncology), M.H. Leiva Gálvez(Institute of Peruvian Studies), Jung‐Yun Lee(Yonsei University), Yulia Kreynina(Sechenov University), Kathryn Howells(AstraZeneca (United States)), Sophie Wildsmith(AstraZeneca (United Kingdom)), Hannah Dry(AstraZeneca (United States)), Ana T. Nunes(AstraZeneca (United States)), Jyoti Mayadev(University of California San Diego Medical Center)
Cited by 15Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis